The Vascular Endothelial Growth Factor Inhibitor Soluble FLT-1 Ameliorates Atopic Dermatitis in APOC1 Transgenic Mice

J Invest Dermatol. 2020 Feb;140(2):491-494.e4. doi: 10.1016/j.jid.2019.07.700. Epub 2019 Aug 16.

Authors

Cleo C L van Aanhold¹, Pascal Bus², Malu Zandbergen², Manon Bos², Jimmy F P Berbée³, Koen D Quint⁴, Jan A Bruijn², Hans J Baelde²

Affiliations

¹ Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: c.c.l.van_aanhold@lumc.nl.
² Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
⁴ Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.

PMID: 31425708
DOI: 10.1016/j.jid.2019.07.700

No abstract available

Publication types

Letter

MeSH terms

Animals
Apolipoprotein C-I / genetics
Dermatitis, Atopic / genetics
Dermatitis, Atopic / immunology
Dermatitis, Atopic / pathology
Dermatitis, Atopic / therapy*
Disease Models, Animal
Female
Genetic Therapy*
Humans
Male
Mice
Mice, Transgenic
Skin / immunology
Skin / pathology
Transfection
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Vascular Endothelial Growth Factor A / immunology
Vascular Endothelial Growth Factor Receptor-1 / genetics*
Vascular Endothelial Growth Factor Receptor-1 / metabolism

Substances

Apolipoprotein C-I
Vascular Endothelial Growth Factor A
vascular endothelial growth factor A, mouse
Flt1 protein, mouse
Vascular Endothelial Growth Factor Receptor-1